HQL
abrdn Life Sciences Investors
NYSE · Financial Services · Asset Management · US
$18.36
+1.32%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- 6.20x
- PEG TTM
- —
- Price / book
- 0.95x
- Price / sales
- 6.14x
- Price / cash flow
- -228.46x
Enterprise value
- Enterprise value
- $529.2M
- EV / sales
- 6.13x
- EV / EBITDA
- 6.18x
- EV / EBIT
- 6.18x
- Market cap
- $530.1M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026